פמטרקסד תרו 100 מ"ג - Pemetrexed taro 100 mg
| ××× ×× ×× × ×ספ×× |
| ||||||
|---|---|---|---|---|---|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | L01BA Folic acid analogues | ||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||
| צ×רת ××ª× | ת××-×ר××× - I.V | ||||||
| צ×רת ××× ×× | ×××§× ×××× ×ª ת×××¡× ×ר×××ת ××¢×ר××, POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||
| ×ת×××× | 1.Pemetrexed Taro in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. 2.Pemetrexed Taro in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. 3.Pemetrexed Taro is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.4.Pemetrexed Taro is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. | ||||||
| |||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| פ×××¨×§×¡× ×ª×¨× 100 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | TARO INTERNATIONAL LTD, ISRAEL |
| ×©× ××¢× ×ר×ש×× | TARO INTERNATIONAL LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 9/2017. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | {{{ת×ר×× ×¢××××}}} |
השינוי האחרון נעשה בֹ־7 באפריל 2023 ב־10:04